For more information call (888) LUHS-888.
The participant must have undergone complete surgical resection (within 6 to 12 weeks prior to enrollment in this trial) of Stage IB-IIIA NSCLC with sampling of at least one mediastinal lymph node. Participant must not have received any prior systemic chemotherapy, be at least 18 years old, and be ambulatory and able to carry out light or sedentary work.
The purpose of this study is to determine if adding the new drug bevacizumab to chemotherapy improves the chance for cure for patients who have had surgery for the removal of the lung cancer and to compare the effects (good and bad) of adding bevacizumab to chemotherapy compared to standard chemotherapy alone. Bevacizumab works by preventing the formation of new blood vessels, including those that surround and supply cancer cells, with the oxygen and nutrients they need to survive and grow.